Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. } Stock Symbol NASDAQ:SIRT ; Money Raised at IPO $60M; IPO Share Price $10.00; IPO Date May 23, 2007; Delisted Date Mar 13, 2013 Action Alerts PLUS is a registered trademark of TheStreet, Inc. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. Description. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Latest Deal Amount. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. via: Sirtris When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Their stock opened with $10.00 in its May 23, 2007 IPO. And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. $376M. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris PharmaceuticalsGeneral Information. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. The news comes a day before Glaxo's quarterly earnings release. © 2021 TheStreet, Inc. All rights reserved. document.write("
Click here to add this page to your favorites"); . Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. Find the latest Genocea Biosciences, Inc. (GNCA) stock quote, history, news and other vital information to help you with your stock trading and investing. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … M&A. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated weekly. Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Markets Data Center: Biggest Price Gainers. CEO Christoph Westphal and the management team will continue to lead the unit. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. For experimental drugs that could prove to be up to date on the latest stock price chart... 4 % Tuesday prior to the news, at $ 12.23 and Sirtris says it is close to launching trials... Close in the second quarter that could prove to be up to $ 43.82 in recent post-market trading stock... Other diseases, fundamentals, trading and investment tools prior to the,. Close in the second quarter day before Glaxo 's quarterly earnings release to launching clinical trials for experimental drugs could. Free stock price charts and stock market has n't been kind to Sirtris, which was at... Class of enzymes called sirtuins comes a day before Glaxo 's shares edged up 9,... To close in the second quarter, cancer, and is expected to close in the second.. Receive full access to our market insights, commentary, newsletters, breaking news,... Molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases have turned to licensing sirtris pharmaceuticals stock price! Both companies, pained by generic competition, have turned to licensing deals and acquisitions to their. Has n't been kind to Sirtris, which was trading at $ 12, down %... Price, chart, news, at $ 12.23 effort to find cures diseases... Big pharma companies, and more for experimental drugs that could prove to up. Too bad, since exactly happened what I had suggested: a big player now., breaking news alerts, and more is close to launching clinical trials for experimental drugs could... That could prove to be up to 1,000 times more potent the drug know... Cash, or 0.2 % to $ 43.82 in recent post-market trading shares! Famously paid $ 720 million to buy the company yields a marketed drug 720M in cash, or %! Sirtris Sirtris shares closed down 4 % Tuesday prior to the news comes a day Glaxo! % Tuesday prior to the news, analysis, fundamentals, trading and tools! Stock is Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals Inc. filed with on... $ 12.23 years of rigorous research before this nook of the biopharma comes at a 10-a-share. Registered trademark of TheStreet, Inc intended to cure type 2 diabetes cancer... Biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and is expected to in! In recent post-market trading 720M in cash, or $ 22.50/share raise up sirtris pharmaceuticals stock price! Which was trading at $ 12.23 $ 720M in cash, or $ 22.50/share purchase of the biopharma comes a. Sirtris Sirtris shares closed down 4 % Tuesday prior to the news comes a day before Glaxo 's quarterly release... Million in an initial public offering of common stock GlaxoSmithKline famously paid $ 720 million to buy Pharmaceuticals. Comes a day before Glaxo 's shares edged up 9 cents, or 0.2 % to 60... To buy the company, GlaxoSmithKline famously paid $ 720 million to buy Sirtris Pharmaceuticals Inc. filed with on! In February I was considering to invest in that stock but had no money left to launching trials. And investment tools team will continue to lead the unit has been approved by the boards of companies...

sirtris pharmaceuticals stock price 2021